PT3538554T - Proteínas de ligação a antigénio que antagonizam o recetor de leptina - Google Patents
Proteínas de ligação a antigénio que antagonizam o recetor de leptinaInfo
- Publication number
- PT3538554T PT3538554T PT178012738T PT17801273T PT3538554T PT 3538554 T PT3538554 T PT 3538554T PT 178012738 T PT178012738 T PT 178012738T PT 17801273 T PT17801273 T PT 17801273T PT 3538554 T PT3538554 T PT 3538554T
- Authority
- PT
- Portugal
- Prior art keywords
- antigen
- binding proteins
- leptin receptor
- antagonize
- antagonize leptin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662419062P | 2016-11-08 | 2016-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3538554T true PT3538554T (pt) | 2025-09-01 |
Family
ID=60409473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT178012738T PT3538554T (pt) | 2016-11-08 | 2017-11-08 | Proteínas de ligação a antigénio que antagonizam o recetor de leptina |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US10550192B2 (enExample) |
| EP (2) | EP4613772A3 (enExample) |
| JP (4) | JP7042816B2 (enExample) |
| KR (1) | KR102563568B1 (enExample) |
| CN (1) | CN110167965A (enExample) |
| AU (2) | AU2017359439B2 (enExample) |
| CA (1) | CA3043365A1 (enExample) |
| CL (3) | CL2019001263A1 (enExample) |
| CO (1) | CO2019004672A2 (enExample) |
| DK (1) | DK3538554T3 (enExample) |
| EA (1) | EA201991075A1 (enExample) |
| ES (1) | ES3040144T3 (enExample) |
| FI (1) | FI3538554T3 (enExample) |
| HR (1) | HRP20251165T1 (enExample) |
| IL (2) | IL266426B (enExample) |
| LT (1) | LT3538554T (enExample) |
| MA (1) | MA45801B1 (enExample) |
| MX (2) | MX2019005397A (enExample) |
| MY (2) | MY191256A (enExample) |
| PH (1) | PH12019500988A1 (enExample) |
| PL (1) | PL3538554T3 (enExample) |
| PT (1) | PT3538554T (enExample) |
| RS (1) | RS67214B1 (enExample) |
| SG (1) | SG10201913470SA (enExample) |
| SI (1) | SI3538554T1 (enExample) |
| SM (1) | SMT202500327T1 (enExample) |
| UA (1) | UA127678C2 (enExample) |
| WO (1) | WO2018089532A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202417497A (zh) | 2015-10-12 | 2024-05-01 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| KR102563568B1 (ko) | 2016-11-08 | 2023-08-04 | 리제너론 파마슈티칼스 인코포레이티드 | 렙틴 수용체에 길항하는 항원-결합 단백질 |
| CA3084385A1 (en) | 2017-12-18 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof |
| EP4596043A3 (en) | 2018-04-06 | 2025-10-01 | Regeneron Pharmaceuticals, Inc. | A leptin receptor agonist antibody for use in increasing bone mass in a subject suffering from metabolic dysfunction or hypoleptinemia |
| WO2020016160A1 (en) * | 2018-07-16 | 2020-01-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to treat neurological diseases |
| KR20210104744A (ko) * | 2018-12-18 | 2021-08-25 | 리제너론 파마슈티칼스 인코포레이티드 | 렙틴 수용체, gdf8 및 액티빈 a에 대한 길항제를 사용하여 체중 및 제지방 근육량을 향상시키기 위한 조성물 및 방법 |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| CN116133628B (zh) * | 2020-07-17 | 2025-04-01 | 住友精化株式会社 | 吸收体 |
| KR20230069969A (ko) * | 2020-09-15 | 2023-05-19 | 리제너론 파마슈티칼스 인코포레이티드 | 통증에 대한 lepr 아고니스트의 사용 |
| CN118436632B (zh) * | 2024-07-05 | 2024-08-30 | 四川大学华西第二医院 | Teriflunomide在制备预防和/或治疗原发性纤毛不动综合征的药物中的用途 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5856098A (en) | 1994-09-14 | 1999-01-05 | Progenitor, Inc. | Detection of a leptin receptor variant |
| US6451523B1 (en) | 1994-09-14 | 2002-09-17 | Interneuron Pharmaceuticals, Inc. | Detection of a leptin receptor variant and methods for regulating obesity |
| US5912123A (en) | 1994-09-14 | 1999-06-15 | Progenitor, Inc. | Detection of the leptin receptor in reproductive organs and methods for regulating reproductive biology |
| US5643748A (en) | 1994-09-14 | 1997-07-01 | Progenitor, Inc. | HU-B1.219, a novel human hematopoietin receptor |
| US6482927B1 (en) | 1995-11-27 | 2002-11-19 | Millennium Pharmaceuticals, Inc. | Chimeric proteins comprising the extracellular domain of murine Ob receptor |
| US6977240B1 (en) | 1995-11-27 | 2005-12-20 | Millenium Pharmaceuticals, Inc. | Methods of using the OB receptor antibodies to treat bodyweight disorders |
| US20050019325A1 (en) | 1996-01-08 | 2005-01-27 | Carter Paul J. | WSX receptor agonist antibodies |
| EP0885299B1 (en) | 1996-01-08 | 2005-10-26 | Genentech, Inc. | Ob receptor and ligands |
| US7063958B1 (en) * | 1996-01-16 | 2006-06-20 | The Rockefeller University | Nucleic acids db, the receptor for leptin |
| AU2476301A (en) | 1996-01-16 | 2001-05-24 | Rockefeller University, The | DB the receptor for leptin nucleic acids encoding the receptor, and uses thereof |
| AU1833197A (en) | 1996-01-18 | 1997-08-11 | Progenitor, Inc. | Detection of a leptin receptor variant and methods for regulating obesity |
| CA2244693A1 (en) | 1996-01-23 | 1997-07-31 | Progenitor, Inc. | Methods for using the obese gene and its gene product to stimulate hematopoietic development |
| US7067472B1 (en) | 1996-06-04 | 2006-06-27 | The Scripps Research Institute | Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies |
| US5965521A (en) | 1997-02-25 | 1999-10-12 | Eli Lilly Company | Pulsatile delivery of leptin receptor ligands |
| IL120733A0 (en) | 1997-04-29 | 1997-08-14 | Yeda Res & Dev | Leptin as an inhibitor of cell proliferation |
| US6696411B1 (en) | 1998-04-22 | 2004-02-24 | Cornell Research Foundation, Inc. | Canine erythropoietin gene and recombinant protein |
| AU767068B2 (en) | 1999-06-11 | 2003-10-30 | Baylor College Of Medicine | Methods and compositions for control of bone formation via modulation of leptin activity |
| US20040253242A1 (en) | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
| FR2852397B1 (fr) | 2003-03-10 | 2005-04-29 | Utilisation des genes leprotl 1 et ob-rgrp pour le criblage de composes actifs sur la prise ou la perte de poids ou le diabete d'un sujet humain ou animal. | |
| DE60314412T2 (de) * | 2003-08-21 | 2008-02-14 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. | Neuer Leptin-Antagonist |
| DE10353593A1 (de) * | 2003-11-17 | 2005-06-23 | Klinikum der Universität München Großhadern-Innenstadt | Leptinantagonist und Verfahren zur quantitativen Messung von Leptin |
| US8969291B2 (en) | 2004-10-08 | 2015-03-03 | Enzo Therapeutics, Inc. | Methods for decreasing leptin levels or activity for treating inflammation |
| US7863240B2 (en) | 2004-10-08 | 2011-01-04 | Enzo Therapeutics, Inc. | Methods and uses of leptin in hepatocellular carcinoma |
| EP1812038A1 (en) | 2004-11-18 | 2007-08-01 | VIB vzw | Fibronectin iii domain as leptin receptor antagonists |
| US7307142B2 (en) * | 2004-11-26 | 2007-12-11 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem | Leptin antagonists |
| WO2006116260A2 (en) | 2005-04-26 | 2006-11-02 | Medimmune, Inc. | Modulation of antibody effector function by hinge domain engineering |
| PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
| US8652466B2 (en) | 2006-12-08 | 2014-02-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
| GB0715216D0 (en) | 2007-08-03 | 2007-09-12 | Asterion Ltd | Leptin |
| CA2742968C (en) | 2008-11-07 | 2020-06-09 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
| CN103298937B (zh) | 2010-11-17 | 2016-05-25 | 中外制药株式会社 | 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子 |
| US20120258073A1 (en) | 2011-02-10 | 2012-10-11 | Christian Gerdes | Immunotherapy |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
| SG10201701831VA (en) | 2012-09-12 | 2017-05-30 | Genzyme Corp | Fc containing polypeptides with altered glycosylation and reduced effector function |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| EP2840892B1 (en) * | 2013-02-20 | 2018-04-18 | Regeneron Pharmaceuticals, Inc. | Non-human animals with modified immunoglobulin heavy chain sequences |
| EP3108255B1 (en) | 2014-02-18 | 2020-08-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway |
| TW202417497A (zh) | 2015-10-12 | 2024-05-01 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| KR102563568B1 (ko) | 2016-11-08 | 2023-08-04 | 리제너론 파마슈티칼스 인코포레이티드 | 렙틴 수용체에 길항하는 항원-결합 단백질 |
-
2017
- 2017-11-08 KR KR1020197016377A patent/KR102563568B1/ko active Active
- 2017-11-08 ES ES17801273T patent/ES3040144T3/es active Active
- 2017-11-08 US US15/807,426 patent/US10550192B2/en active Active
- 2017-11-08 MA MA45801A patent/MA45801B1/fr unknown
- 2017-11-08 WO PCT/US2017/060690 patent/WO2018089532A1/en not_active Ceased
- 2017-11-08 SI SI201731619T patent/SI3538554T1/sl unknown
- 2017-11-08 EA EA201991075A patent/EA201991075A1/ru unknown
- 2017-11-08 DK DK17801273.8T patent/DK3538554T3/da active
- 2017-11-08 EP EP25187542.3A patent/EP4613772A3/en active Pending
- 2017-11-08 LT LTEPPCT/US2017/060690T patent/LT3538554T/lt unknown
- 2017-11-08 CN CN201780082335.4A patent/CN110167965A/zh active Pending
- 2017-11-08 SM SM20250327T patent/SMT202500327T1/it unknown
- 2017-11-08 HR HRP20251165TT patent/HRP20251165T1/hr unknown
- 2017-11-08 MY MYPI2019002549A patent/MY191256A/en unknown
- 2017-11-08 EP EP17801273.8A patent/EP3538554B1/en active Active
- 2017-11-08 FI FIEP17801273.8T patent/FI3538554T3/fi active
- 2017-11-08 MY MYPI2022002957A patent/MY203682A/en unknown
- 2017-11-08 JP JP2019523865A patent/JP7042816B2/ja active Active
- 2017-11-08 CA CA3043365A patent/CA3043365A1/en active Pending
- 2017-11-08 RS RS20250925A patent/RS67214B1/sr unknown
- 2017-11-08 AU AU2017359439A patent/AU2017359439B2/en active Active
- 2017-11-08 SG SG10201913470SA patent/SG10201913470SA/en unknown
- 2017-11-08 PT PT178012738T patent/PT3538554T/pt unknown
- 2017-11-08 MX MX2019005397A patent/MX2019005397A/es unknown
- 2017-11-08 UA UAA201906354A patent/UA127678C2/uk unknown
- 2017-11-08 PL PL17801273.8T patent/PL3538554T3/pl unknown
-
2019
- 2019-05-02 IL IL266426A patent/IL266426B/en active IP Right Grant
- 2019-05-03 PH PH12019500988A patent/PH12019500988A1/en unknown
- 2019-05-07 CO CONC2019/0004672A patent/CO2019004672A2/es unknown
- 2019-05-08 MX MX2023011233A patent/MX2023011233A/es unknown
- 2019-05-08 CL CL2019001263A patent/CL2019001263A1/es unknown
-
2020
- 2020-01-07 US US16/736,760 patent/US11535675B2/en active Active
- 2020-01-30 IL IL272358A patent/IL272358B/en unknown
- 2020-03-05 CL CL2020000549A patent/CL2020000549A1/es unknown
- 2020-04-16 CL CL2020001023A patent/CL2020001023A1/es unknown
-
2021
- 2021-12-21 JP JP2021206917A patent/JP2022031969A/ja active Pending
-
2022
- 2022-11-17 US US18/056,411 patent/US20230235068A1/en active Pending
-
2023
- 2023-05-02 JP JP2023076083A patent/JP7611292B2/ja active Active
-
2024
- 2024-05-31 JP JP2024088870A patent/JP2024109952A/ja active Pending
-
2025
- 2025-02-28 AU AU2025201454A patent/AU2025201454A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201913432RA (en) | Antigen-binding proteins that activate the leptin receptor | |
| ZA201900353B (en) | Anti-pd-l1 antibodies | |
| HUS2500024I1 (hu) | ANTI-PD-1 ellenanyagok | |
| SG10201913470SA (en) | Antigen-binding proteins that antagonize leptin receptor | |
| ZA201803874B (en) | Humanized anti-cd73 antibodies | |
| IL262295A (en) | Antibodies against pd-l1 | |
| SG11202001368SA (en) | Antigen-binding proteins tatrgeting shared antigens | |
| SI3512547T1 (sl) | Anti-PD-1 protitelesa | |
| IL257062A (en) | New anti-pd-1 antibodies | |
| EP3274366B8 (en) | Chimeric antigen receptor | |
| IL253909A0 (en) | Humanized *anti–muc1 antibodies | |
| IL259492B (en) | Humanized antibodies against cll–1 | |
| SG11201705552QA (en) | Anti-pd-l1 antibodies | |
| GB201503742D0 (en) | Chimeric antigen receptor | |
| SG11202013138RA (en) | Anti-steap1 antigen-binding protein | |
| ZA201807167B (en) | Humanized anti-il-1r3 antibodies | |
| IL256579A (en) | Human antibodies | |
| PT3101131T (pt) | Anticorpo antitranstirretina humanizado | |
| EP3119812A4 (en) | Bi-specific antigen-binding polypeptides | |
| PL3371216T3 (pl) | Humanizowane przeciwciała anty-BAG3 | |
| HK40006638A (en) | Antigen-binding proteins that antagonize leptin receptor | |
| GB201804154D0 (en) | Optimisation methods |